NCT02747030View on ClinicalTrials.gov

Phase I RVC With Ocriplasmin for CRVO

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 10, 2017

Study Completion Date

August 11, 2017

Conditions
Central Retinal Vein Occlusion
Interventions
DRUG

Ocriplasmin intravenously

Retinal vein cannulation with Ocriplasmin infusion

Trial Locations (1)

3000

UZ Leuven, Leuven

All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT02747030 - Phase I RVC With Ocriplasmin for CRVO | Biotech Hunter | Biotech Hunter